CRISPR Therapeutics AG (CRSP)

NASDAQ • Healthcare

$49.39

-$0.6 (-1.2%)

Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$49.31

Day Range$48.02 - $49.64

Avg. Volume (3M)1.5M

Market Cap$4.7B

52 Week Range

$44.12$67.73

Next EarningsIn 16 daysNov 9, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

$13.3M

Net Income (TTM)

-$451.1M

EPS (TTM)

-$4.76

ROA (TTM)

-17.02%

Current Ratio

17.85

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-63.3%Q3 2025-$2.4

+7.1%Q4 2025-$1.17

-19.1%Q1 2026-$1.37

-7.6%Q2 2026-$1.28

+21.0%Q3 2026-$0.94

Nov 9

in 16 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +21.0%

CRISPR Therapeutics beat expectations on earnings in the second fiscal quarter of 2026, reported August 3, as EPS of -$0.94 topped the -$1.19 estimate (+21.0%) and improved from -$2.40 a year ago. Net income was a loss of roughly $91.2 million, improving +56% year over year from a loss of about $208.5 million, while operating income came in at a loss of about $114.8 million. Cash flow remained negative, with negative operating cash flow of roughly $192.4 million during the quarter. For the next period, consensus calls for EPS of $-1.06 on revenue of $14.8 million.

Next report — what to expect

CRISPR Therapeutics AG (CRSP) reports next on November 9, 2026. With consensus figures not provided here, the main setup is its recent variability: CRSP has beaten EPS in 4 of its 8 most recent quarters, so traders may focus on whether results and commentary align with that mixed pattern.

View full earnings history

About CRISPR Therapeutics AG

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on gene-edited medicines. In qualitative terms it is a clinical-stage healthcare business built around CRISPR/Cas9, which it uses to alter genetic code, with programs spanning ex vivo therapies, allogeneic CAR-T candidates, and stem cell-derived approaches.

Name

CRISPR Therapeutics AG

CEO

Samarth Kulkarni

Website

www.crisprtx.com

Industry

Healthcare

Year Founded

2013

Employees

393

Today's Snapshot

AI-generated

The day ended with CRSP 1.2% lower at 49.39, in line with a weaker sector.

Trading Volume

Above 10d avg 1.4M

1.8M

vs S&P 500 Today

Underperforming Market

-0.68%

Updated: October 23, 2026 at 20:08 UTC

CRSP Headlines

Fresh Valuation Checks Across Key Stocks

April 4, 2026

6 min read

Biotech ETFs Flash Classic Reversal Signal

April 1, 2026

2 min read

View All News

Technical Indicators

1 Buy1 Neutral6 Sell

CRSP reflects a sell bias as the price trades below its short-, medium- and 200-day moving averages and beneath the pivot, with on-balance volume negative and indicating distribution. Momentum is weak to bearish with MACD below zero and ten-day momentum negative, while RSI is muted and stochastic offers limited short-covering potential. ADX is low, implying the downtrend lacks strong directional conviction, and ATR is elevated relative to price, signaling larger swings. Overall the balance of price, momentum and volume leans toward sellers. Technical takeaway: Price, momentum and volume favor a sell stance.

All signals

EMA (5 indicators)$50.56 - $53.79
Sell
RSI (14)40.49
Neutral
Stochastic %K (14, 3, 3)19.52
Buy
MACD Level (12, 26)-1.41
Sell

Peers & Related Assets

BEAMBeam Therapeutics Inc.

$24.05-2.1%

NTLAIntellia Therapeutics, Inc.

$11.21+0.5%

RGNXREGENXBIO Inc.

$6.68-6.8%

EDITEditas Medicine, Inc.

$2.4-3.6%

DNAGinkgo Bioworks Holdings, Inc.

DTILPrecision BioSciences, Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.